INSULINOTROPIC PEPTIDE SYNTHESIS USING SOLID AND SOLUTION PHASE COMBINATION TECHNIQUES
    1.
    发明申请
    INSULINOTROPIC PEPTIDE SYNTHESIS USING SOLID AND SOLUTION PHASE COMBINATION TECHNIQUES 审中-公开
    使用固相和溶液相组合技术的胰岛素肽合成

    公开(公告)号:US20110213082A1

    公开(公告)日:2011-09-01

    申请号:US13105435

    申请日:2011-05-11

    IPC分类号: C08G61/00 C07K7/08

    CPC分类号: C07K14/605 A61K38/00

    摘要: The present invention relates to the preparation of insulinotropic peptides that are synthesized using a solid and solution phase (“hybrid”) approach. Generally, the approach includes synthesizing three different peptide intermediate fragments using solid phase chemistry. Solution phase chemistry is then used to add additional amino acid material to one of the fragments. The fragments are then coupled together in the solid solution phase. The use of a pseudoproline in one of the fragments eases solid phase synthesis of that fragment and also eases subsequent solution phase coupling of this fragment to other fragments. The present invention is very useful for forming insulinotropic peptides such as GLP-1(7-36) and its natural and non-natural counterparts.

    摘要翻译: 本发明涉及使用固相和溶液相(“混合”)方法合成的促胰岛素肽的制备。 通常,该方法包括使用固相化学合成三种不同的肽中间体片段。 然后使用溶液相化学为其中一个片段添加另外的氨基酸材料。 然后将片段在固溶相中偶联在一起。 在其中一个片段中使用假脯氨酸使得该片段的固相合成减轻了该片段随后与其它片段的溶液相偶联。 本发明对于形成促胰岛素肽如GLP-1(7-36)及其天然和非天然对应物非常有用。

    Insulinotropic peptide synthesis using solid and solution phase combination techniques
    2.
    发明授权
    Insulinotropic peptide synthesis using solid and solution phase combination techniques 失效
    使用固相和溶液相组合技术的胰岛素肽合成

    公开(公告)号:US08227571B2

    公开(公告)日:2012-07-24

    申请号:US12316309

    申请日:2008-12-11

    IPC分类号: C07K14/00

    CPC分类号: C07K14/605

    摘要: The present invention relates to the preparation of insulinotropic peptides that are synthesized using a solid and solution phase (“hybrid”) approach. Generally, the approach includes synthesizing three different peptide intermediate fragments using solid phase chemistry. Solution phase chemistry is then used to add additional amino acid material to the third fragment which is then coupled to the second fragment and then the first fragment in solution. Alternatively, a different second fragment is coupled to the first fragment in the solid phase. Then, solution phase chemistry is then used to add additional amino acid material to a different third fragment. Subsequently, this different third fragment is coupled to the coupled first and different second fragment in the solution phase. The use of a pseudoproline in one of the fragments eases solid phase synthesis of that fragment and also eases subsequent solution phase coupling of this fragment to the other fragments. The present invention is very useful for forming insulinotropic peptides such as GLP-1(7-36) and its natural and non-natural counterparts.

    摘要翻译: 本发明涉及使用固相和溶液相(“混合”)方法合成的促胰岛素肽的制备。 通常,该方法包括使用固相化学合成三种不同的肽中间体片段。 然后使用溶液相化学为第三片段添加另外的氨基酸材料,然后将其与第二片段偶联,然后与溶液中的第一片段偶联。 或者,不同的第二片段与固相中的第一片段偶联。 然后,然后使用溶液相化学法将另外的氨基酸材料添加到不同的第三片段。 随后,将该不同的第三片段与溶液相中的偶联的第一和不同的第二片段偶联。 在其中一个片段中使用假脯氨酸使得该片段的固相合成减轻了该片段随后与其它片段的溶液相偶联。 本发明对于形成促胰岛素肽如GLP-1(7-36)及其天然和非天然对应物非常有用。

    Methods for the synthesis of cyclic peptides
    3.
    发明申请
    Methods for the synthesis of cyclic peptides 审中-公开
    合成环肽的方法

    公开(公告)号:US20080287649A1

    公开(公告)日:2008-11-20

    申请号:US12004265

    申请日:2007-12-20

    IPC分类号: C07K2/00 C07C69/616 C07K5/12

    摘要: Methods for the synthesis of cyclic peptides are provided, as well as novel dipeptide compounds. The methods include the solid phase synthesis of a dipeptide, which is the coupled to a second peptide in a solid phase reaction. The peptide is then cyclized following the coupling reaction. The methods and dipeptides are particularly useful for the synthesis of MC-4 receptor agonist peptides.

    摘要翻译: 提供了合成环肽的方法,以及新型二肽化合物。 所述方法包括在固相反应中与第二肽偶联的二肽的固相合成。 然后在偶合反应后使肽环化。 该方法和二肽特别可用于合成MC-4受体激动剂肽。

    Insulinotropic peptide synthesis using solid and solution phase combination techniques
    4.
    发明申请
    Insulinotropic peptide synthesis using solid and solution phase combination techniques 失效
    使用固相和溶液相组合技术的胰岛素肽合成

    公开(公告)号:US20090292108A1

    公开(公告)日:2009-11-26

    申请号:US12316309

    申请日:2008-12-11

    IPC分类号: C07K1/02 C07K14/00 C07K7/06

    CPC分类号: C07K14/605

    摘要: The present invention relates to the preparation of insulinotropic peptides that are synthesized using a solid and solution phase (“hybrid”) approach. Generally, the approach includes synthesizing three different peptide intermediate fragments using solid phase chemistry. Solution phase chemistry is then used to add additional amino acid material to the third fragment which is then coupled to the second fragment and then the first fragment in solution. Alternatively, a different second fragment is coupled to the first fragment in the solid phase. Then, solution phase chemistry is then used to add additional amino acid material to a different third fragment. Subsequently, this different third fragment is coupled to the coupled first and different second fragment in the solution phase. The use of a pseudoproline in one of the fragments eases solid phase synthesis of that fragment and also eases subsequent solution phase coupling of this fragment to the other fragments. The present invention is very useful for forming insulinotropic peptides such as GLP-1(7-36) and its natural and non-natural counterparts.

    摘要翻译: 本发明涉及使用固相和溶液相(“混合”)方法合成的促胰岛素肽的制备。 通常,该方法包括使用固相化学合成三种不同的肽中间体片段。 然后使用溶液相化学为第三片段添加另外的氨基酸材料,然后将其与第二片段偶联,然后与溶液中的第一片段偶联。 或者,不同的第二片段与固相中的第一片段偶联。 然后,然后使用溶液相化学法将另外的氨基酸材料添加到不同的第三片段。 随后,将该不同的第三片段与溶液相中的偶联的第一和不同的第二片段偶联。 在其中一个片段中使用假脯氨酸使得该片段的固相合成减轻了该片段随后与其它片段的溶液相偶联。 本发明对于形成促胰岛素肽如GLP-1(7-36)及其天然和非天然对应物非常有用。

    Process for preparing a
2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol
derivative
    9.
    发明授权
    Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative 失效
    制备2-(2-氨基-1,6-二氢-6-氧代 - 嘌呤-9-基)甲氧基-1,3-丙二醇衍生物的方法

    公开(公告)号:US6103901A

    公开(公告)日:2000-08-15

    申请号:US121446

    申请日:1998-07-23

    CPC分类号: C07D473/18 Y02P20/55

    摘要: Intermediates of Formula (III) ##STR1## wherein P.sup.1 is hydrogen or an amino-protecting group, R is lower alkyl, allyl or aralkyl, and Z is hydrogen, lower alkyl, aryl or aralkyl; and Formula (VI) ##STR2## wherein P.sup.1 is hydrogen or an amino-protecting group, P.sup.2 is an amino protecting group, and Z is hydrogen, lower alkyl, aryl or aralkyl, are useful in a novel process for preparing the mono-L-valine ester of 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol (ganciclovir). The mono-L-valine ester of ganciclovir and its pharmaceutically acceptable salts are of value as antiviral agents with improved absorption.

    摘要翻译: 其中P1为氢或氨基保护基的式(III)中间体,R为低级烷基,烯丙基或芳烷基,Z为氢,低级烷基,芳基或芳烷基; 和式(VI)其中P1是氢或氨基保护基,P2是氨基保护基,Z是氢,低级烷基,芳基或芳烷基,可用于制备单-L-缬氨酸酯的新方法 的2-(2-氨基-1,6-二氢-6-氧代 - 嘌呤-9-基)甲氧基-1,3-丙二醇(更昔洛韦)。 更昔洛韦的单-L-缬氨酸酯及其药学上可接受的盐具有改善吸收的抗病毒剂的价值。